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The Roles of FMRP-Regulated Genes
in Autism Spectrum Disorder:
Single- and Multiple-Hit Genetic Etiologies
Julia Steinberg1,2 and Caleb Webber1,*
Autism spectrum disorder (ASD) is a highly heritable complex neurodevelopmental condition characterized by impairments in social
interaction and communication and restricted and repetitive behaviors. Although roles for both de novo and familial genetic variation
have been documented, the underlying disease mechanisms remain poorly elucidated. In this study, we defined and explored distinct
etiologies of genetic variants that affect genes regulated by Fragile-X mental retardation protein (FMRP), thought to play a key role in
neuroplasticity and neuronal translation, in ASD-affected individuals. In particular, we developed the Trend test, a pathway-association
test that is able to robustly detect multiple-hit etiologies and is more powerful than existing approaches. Exploiting detailed spatiotem-
poral maps of gene expression within the human brain, we identified four discrete FMRP-target subpopulations that exhibit distinct
functional biases and contribute to ASD via different types of genetic variation. We also demonstrated that FMRP target genes are
more likely than other genes with similar expression patterns to contribute to disease. We developed the hypothesis that FMRP targets
contribute to ASD via two distinct etiologies: (1) ultra-rare and highly penetrant single disruptions of embryonically upregulated FMRP
targets (‘‘single-hit etiology’’) or (2) the combination of multiple less penetrant disruptions of nonembryonic, synaptic FMRP targets
(‘‘multiple-hit etiology’’). The Trend test provides rigorous support for a multiple-hit genetic etiology in a subset of autism cases and
is easily extendible to combining information from multiple types of genetic variation (i.e., copy-number and exome variants),
increasing its value to next-generation sequencing approaches.Introduction
Autism spectrum disorder (ASD [MIM 209850]) is a neuro-
logical early-onset condition characterized by restricted in-
terests, repetitive behavior, and impairments in social
communication; it affects ~1% of the population. The eti-
ology of ASD still remains to be elucidated, although twin
and family studies have shown that ASD is highly herita-
ble1 at around 80%.2 Linkage, association, and copy-num-
ber variant (CNV) studies have identified a role for both de
novo and familial variation.3–5 The list of ASD candidate
genes is steadily increasing, but no single locus accounts
for >1% of cases.6
Although ASD is predominantly a complex disorder,
approximately 5% of cases are due to a high comorbidity
with the monogenic Fragile-X syndrome (FXS [MIM
300624]), the most common single-gene defect associated
with ASD.7 FXS is caused by a loss of function of Fragile-X
mental retardation protein (FMRP),8 a neuronal and
gonadal protein with key roles in neuroplasticity and
neuronal translation.9 Under normal function, FMRP has
been reported to negatively regulate translation by stalling
ribosomal translocation across the mRNA of 842 genes
(herein termed ‘‘FMRP targets’’), including a significantly
large number of previously identified ASD candidates
genes.10 A recent exome sequencing study by Iossifov
et al.11 found that genes affected by exonic de novo1Medical Research Council Functional Genomics Unit, Department of Physio
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. Open access unonsense, splice-site, and frameshift mutations identified
in ASD probands are significantly enriched in FMRP
targets; the authors replicated the enrichment in an analo-
gous ASD candidate gene set compiled by three other
exome sequencing studies.12–14 However, the role of
FMRP regulation has yet to be fully elucidated; genes tar-
geted by FMRP play diverse roles in both embryonic and
adult neurogenesis and in synapse structure and func-
tion.15,16 Thus, the causal relationship between the dysre-
gulation of the 842 FMRP targets in FXS and the general
pathology of ASD is unclear: whether all FMRP target genes
causally contribute to ASD and whether those that do
act through common or diverse mechanisms remain
unknown. Other previous pathway analyses of ASD have
separately implicated synaptic genes17–21 and chromatin
modifiers,12 as well as embryonic transcription regula-
tors.22 These separate studies have focused on particular
types of genetic variation, whereas a holistic model of
genetic causality in ASDwithin which these different types
of variation canbe interpretedhasnot yet beendetermined.
We hypothesized that different classes of sequence vari-
ants contribute to ASD to varying extents. Thus, we consid-
ered the role played by FMRP targets in ASD across the
spectrum of genetic variation by exploiting data from
SNPs, copy-number variants (CNVs), and disrupting
single-gene de novomutations (Table S1, available online).
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singularly sufficient to cause ASD, variants inherited from
unaffected parents are necessarily of incomplete pene-
trance. In particular, the presence of multiple CNVs in
many individuals with ASD23,24 suggests that inherited
variation might lead to ASD through cumulative effects
of deleterious variants affecting a relevant biological
pathway (a ‘‘multiple-hit’’ disease mechanism). This hy-
pothesis is also supported by the observed influence of
background variation on phenotypes in model organ-
isms25 and could explain the phenotypic heterogeneity
observed for variants associated with a range of neuropsy-
chiatric phenotypes.24
In this systematic analysis of FMRP targets in ASD, we
developed and explored the hypothesis that different
groups of FMRP targets contribute to ASD in distinct
ways; we did this most notably by distinguishing those
genes affected by highly penetrant, de novo gene disrup-
tions that tend to contribute via a single-hit etiology
from those genes affected by less penetrant, inherited var-
iants that tend to contribute via a multiple-hit etiology.
First, we showed that comprehensive expression data
from human brains reveal subgroups (modules) of FMRP
targets with distinct spatiotemporal expression patterns
and biological roles. Second, we examined the contribu-
tion of individual FMRP target modules to the overlap
with ASD candidate genes on the basis of de novo single-
gene disruptions. Third, we developed an approach to con-
ducting gene-set analysis on the basis of gene disruptions
found in CNV case-control data sets. Importantly, our
approach explicitly considers the contribution of multiple
gene disruptions in each individual and is demonstrably
more powerful than approaches applied previously. Using
this approach, we then examined the disruptions of FMRP
target modules in rare CNVs and considered the associa-
tion between SNPs located in FMRP targets and ASD diag-
nosis. Finally, we investigated whether the association
between FMRP targets and ASD can be extended to genes
with brain expression patterns similar to those of specific
FMRP target subgroups and demonstrated that FMRP target
genes are more likely to cause disease.Material and Methods
Ethics Statement
Institutional-review-board approval and informed consent were
given for all data sets in previously published papers.De Novo Single-Gene Disruptions in ASD Data
Lists of genes disrupted by de novo nonsense, frameshift, or splice-
site point mutations in autism probands were obtained from
Iossifov et al.11 (59 genes; referred to as ‘‘I-exomes’’) and three
other recent studies by Sanders et al.,12 O’Roak et al.,13 and Neale
et al. 14 (65 genes combined from all three; referred to as ‘‘SON-
exomes’’) (Table S1, available online). A list of genes disrupted by
breakpoints of balanced chromosomal abnormalities (BCAs)
observed in individuals with ASD was obtained from Talkowski
et al.26 (32 genes; referred to as ‘‘T-BCAs’’) (Table S1).826 The American Journal of Human Genetics 93, 825–839, NovembNational Blood Service CNV Data
The CNV data for the National Blood Service (NBS) cohort were
provided by the Wellcome Trust Case Control Consortium 1
(WTCCC1,27 09/02/09 release) after quality control, and CNVs
were called from an Affymetrix 500k chip with SWArray (1,343 in-
dividuals). We only considered deletions R 1 kb, with at least
three probes, and with a confidence score R 0.2 (false-discovery
rate [FDR] was estimated at 22% by the WTCCC1; note that we
only used this data set for simulations and therefore did not
require very high call accuracy).
ASD CNV Data
All rare deletion CNVs that passed quality control were taken from
Sanders et al.;28 we compared 872 probands to their matched un-
affected siblings and compared 1,124 probands to their 2,248 par-
ents (Table S1). Moreover, all rare deletion CNVs from ASD
probands and unaffected controls passing quality controls from
an Autism Genome Project (AGP) study29 were provided by the
AGP Consortium (Table S1). In the AGP set, individuals with
CNVs were subdivided into two groups on the basis of whether
they met the strict criteria for ASD diagnosis (autism was diag-
nosed according to both the Autism Diagnostic Observation
Schedule30 and the Autism Diagnostic Interview, Revised31); to
consider only ‘‘strict autism’’ cases in our analysis, we did not
include individuals without CNVs. Following the original defini-
tions, Sanders et al. classified a CNV as rare if%50% of its length
overlapped regions present at >1% frequency in the Database of
Genomic Variants of March 2010;28 for the AGP CNV data set, a
CNVwas classified as rare if it was present in<1% of the AGP total
sample.29
ASD SNP Data
We obtained access to an autism family-based genotype data set
(‘‘CHOP_cleaned’’) with partial quality control from the Autism
Genetic Resource Exchange (AGRE). A subset of the data was uti-
lized in a genome-wide association study (GWAS) by Wang
et al.,32 and we tried to match their filtering steps as closely as
possible (see Appendix A). The final set consisted of 472,487 auto-
somal SNPs, 1,334 cases, and 1,764 controls (Table S1). From the
transmission disequilibrium test for all autosomal SNPs, the
genomic control was calculated as 1.04, matching the value
from Wang et al.;32 the p values for the most associated SNPs
were also similar to those calculated by Wang et al.32 (Table S2).
FMRP Targets
Brain Specificity
We obtained expression levels for 17,226 human genes with
Ensembl gene IDs33,34 from the GNF2 expression atlas35 and
further considered 4 fetal and 31 adult tissues (Table S3). For each
geneG,we calculated the ratio of expression in the brain to theme-
dian of all tissues separately for fetal and adult tissues and obtained
the brain-specificity ratios BrainSpecfetal(G) and BrainSpecadult(G),
respectively. We used logistic regression to determine whether
BrainSpecadult or being an FMRP target (indicator variable) had sig-
nificant effects on theprobability that a genewouldbe foundas dis-
rupted in ASD in I-exomes, SON-exomes, and T-BCAs from above,
as well as in a combined list of the three. The analysis was repeated
for BrainSpecfetal instead of BrainSpecadult.
Coding-Sequence Length
We obtained the coding-sequence (CDS) length of all protein-cod-
ing genes with Ensembl gene IDs from Ensemblmart (downloadeder 7, 2013
June 17, 2013). Each gene was assigned the maximumCDS length
of its transcripts.
Coexpression and Temporal Specificity
Normalized gene expression data determined by RNA sequencing
and representing 16 human brain regions were obtained via Brain-
Span (downloaded May 8, 2012; 41 individuals). A total of 14,886
genes with Ensembl gene IDs and at least one read per kilobase per
million (RPKM) inR95% of the samples were kept; these included
832 of the 842 reported FMRP targets.10 We used the R package
WGCNA (weighted correlation network analysis)36 according to
the procedure (including parameterization) recommended by
the authors to cluster the 832 FMRP targets according to their
expression patterns.
Six developmental stages were defined as suggested by the
experimental proceedings of BrainSpan. For each gene, the expres-
sion level at a developmental stage was calculated as the median
expression level across all samples (individuals and brain areas)
from that time period.We noticed that themedian expression dur-
ing the stage of ‘‘childhood’’ was generally lower for all human
genes, and we accounted for this by increasing median expression
by a constant factor (see Appendix A).
Functional Enrichment
A total of 7,271 GO_BP_FAT (Gene Ontology [GO] Biological Pro-
cesses) and 1,031 GO_CC_FAT (GO Cellular Compartment) gene
sets (‘‘pathways’’) were downloaded from the Database for Annota-
tion, Visualization, and Integrated Discovery (DAVID)37 (on June
15, 2012). To reduce multiple-testing and uninformative re-
sults,38 we further considered only 262 pathways that contained
R250 genes.
Insights into a gene’s function can also be gained by consider-
ation of the phenotypes that result from the disruption of that
gene’s unique ortholog in a model organism.39,40 We proceeded
as did Shaikh et al.41 In brief, we obtained the phenotypes ex-
hibited by mouse models possessing a targeted disruption of a
protein-coding gene from Mouse Genomics Informatics (MGI;
downloaded November 16, 2011). The annotations consist of 30
general (overarching) phenotypes with finer terms in multiple
hierarchical levels.42 Using 1:1 orthology between mouse and hu-
man genes defined by MGI, we mapped all mouse phenotypes to
the human ortholog genes to obtain mouse phenotype assign-
ments for 6,401 human genes. For each phenotype, the assigned
human genes were referred to as a ‘‘pathway.’’ To reduce uninfor-
mative results, we only considered subphenotypes assigned to at
least 1% of the genes of the overarching phenotype.38
Haploinsufficiency
Huang et al.43 reported the probability of haploinsufficiency for
12,218 genes with Ensembl gene IDs. We defined haploinsuffi-
cient (‘‘HIS’’) genes by applying a probability cutoff of R0.5
(3,362 genes). We confirmed pairwise differences in the distribu-
tion of HIS probabilities between gene sets (Figure S1).
Testing Differences between Gene Lists
For functional annotations and HIS genes, enrichment among a
gene list was tested with a one-sided hypergeometric test, using
a 5% Benjamini-Hochberg FDR for each pathway list. GO and
MGI enrichments among FMRP modules were tested with all
FMRP targets as the background; otherwise, the background con-
sisted of all annotated genes. Differences in annotations between
two gene lists were tested with a two-sided Fisher’s test. Differences
in distributions of haploinsufficiency probabilities and brain
specificity (separately for fetal and adult tissues) between two
gene lists were tested with a two-sided Mann-Whitney U-test in
R (v.2.13.0).The AmericanVariation in the Human Population
Single-nucleotide variants discovered by exome sequencing
were downloaded from the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project Exome Variant
Server (ESP5400 release). Gene symbols were mapped to Ensembl
gene IDs; only exonic variants in protein-coding genes found
in individuals of European ancestry were considered (yielding
variants for 17,846 genes; 279 genes in FMRP module 1 and
235 in module 2). For each gene, we calculated the proportion
of variants that had a minor allele frequency (MAF) < 0.02%
(‘‘ultra-rare’’), 0.02%–1% (‘‘rare-not-ultra-rare’’), or >1% (‘‘com-
mon’’). For each of the frequency categories, the pairwise differ-
ences in distribution of proportions between gene sets was
calculated with a Mann-Whitney U-test in R and corrected
for multiple testing at 5% FDR. In the second step, we repeated
all calculations by considering only those variants classified
as missense mutations, splice-site mutations, or mutations intro-
ducing or removing stop codons. Finally, we repeated the calcu-
lations for variants assigned a PolyPhen44 score of ‘‘probably
damaging’’ or ‘‘possibly damaging’’ (contained in the down-
loaded data).Methods for CNV Pathway Analysis
Trend and Fisher’s Tests for CNVs
For each individual, CNV coordinates in NCBI36 were compared
to gene-transcript locations from Ensembl mart 54.33,34 Conserva-
tively, a gene was defined as ‘‘hit’’ if a CNVoverlapped at least one
exon for every transcript of that gene. A pathway was defined as
‘‘hit’’ if at least one gene from the pathway was hit by CNVs in
that individual. A pathway was defined as ‘‘hit h times’’ in an indi-
vidual if h genes in that pathway were hit by CNVs in that individ-
ual. A Fisher’s test statistic was obtained from a two-sided exact
Fisher’s test on the numbers of cases and controls with and
without hits. We developed the Trend test as a Cochran-Armitage
test for trend in the number of cases and controls with h hits as h
increased (after pooling numbers when there were too few obser-
vations for large h, see Appendix A); we weighted observations
for h hits by
ﬃﬃﬃ
h
p
(see Appendix A).
Matching Random Gene Sets to a Pathway
It is crucial to account for differences in CNV burden between
cases and controls to avoid false-positive pathway associations.45
We chose to account for differences in general CNV burden be-
tween cases and controls through randomizations and obtained
an empirical Trend test p value for a pathway from random gene
sets matched for the number of genes and the gene lengths. To
match by gene length, we divided all human protein-coding genes
(21,219 downloaded from Ensembl mart 54) by their gene length
into 100 bins, b(1), ..., b(100), of equal size. If a pathway P had
p(1), ... p(100) genes from the respective bins, we obtained a
random gene set by sampling p(i) genes without replacement
from bins i ¼ 1, ..., 100.
Test for Risk Conferred by Multiple Hits
We noted that a significant association from the Trend test could
also result from a single-hit disease model and would therefore
not be sufficient to show a multiple-hit model of disease. Conse-
quently, we developed the following testing procedure for path-
ways with significant results from the Trend test and the
occurrence of multiple hits in several individuals. For a given
case-control data set and a pathway P of interest, we calculated
the numbers of cases and controls with h hits, h ¼ 1, ..., m
(after pooling hits with too few observations, see Appendix A).Journal of Human Genetics 93, 825–839, November 7, 2013 827
We then defined the sequence (R0 (h))h ¼ 1,...,m as
R
0ðhÞ¼number of cases with h hits=number of cases with h hitsþ
number of controls with h hits for h¼ 1, ...,m. A linear model was
fitted to (R0 (h))h ¼ 1,...,m on the basis of an intercept and the num-
ber of hits h. If the regression coefficient C for the number of hits
was significant at single-test level, we obtained a one-sided empir-
ical p value by calculating the proportion of 10,000 random path-
ways matched to P for which the coefficient C(rand) for the num-
ber of hits was also significant at single-test level and at least as
large as C.
ASD De Novo Single-Gene Mutation Enrichment in
FMRP Targets
We tested the enrichment of all FMRP targets and the four FMRP
modules in the genes found disrupted in I-exomes, SON-exomes,
and T-BCAs (Table S1) by using the right-tailed hypergeometric
test and a conservative estimate of 15,000 genes as the back-
ground. Multiple testing for FMRP modules was corrected at 5%
FDR for each data set. We also considered the pairwise overlap of
I-exomes, SON-exomes, and T-BCAs: no overlap existed between
T-BCAs and I-exomes, and no FMRP target was in both I-exomes
and SON-exomes. To account for the overlap of T-BCAs and
SON-exomes, we also performed an enrichment test for T-BCAs
in which the genes found in SON-exomes were excluded. We
also applied logistic regression to account for CDS length and (1)
adult-brain specificity and (2) fetal-brain specificity when testing
the enrichment of all FMRP targets. Additionally, we applied logis-
tic regression to account for CDS length when analyzing the asso-
ciation of FMRP modules (because neither brain-specificity index
was significantly associated with I-exomes, SON-exomes, or
T-BCAs, we did not include brain specificity in this analysis).
ASD Trend-Test CNV Pathway Analysis Using FMRP
Modules
We used the Trend test to examine the role of all FMRP targets and
modules 1–4 in rare deletion CNVs in ASD. ASD probands and
their unaffected siblings from Sanders et al.28 were used as a dis-
covery cohort; the expanded set of probands and their parents
were used for further validation. AGP ‘‘strict autism’’ cases and
controls were used as a final replication sample.29 Empirical
p values were obtained with 10,000 random gene sets matched
to a pathway of interest as described above. Multiple testing for
FMRP modules was corrected at 5% FDR for each data set.
ASD SNP Pathway Analysis Using FMRP Modules
On the basis of the AGRE SNP data set, for FMRP modules 1–4, we
assigned each autosomal SNP to amodule if it was located between
the gene start and end based on GRCh37 (Ensembl). For each
module, we then carried out a set-based association test in Plink
to obtain empirical p values for the average chi-square statistic
for eachmodule from 100,000 permutations of case-control status.
To account for linkage disequilibrium, we only took into account
SNPs considered independent under an r2 threshold of 0.5; as the
only significant module, module 2 was also tested with r2 thresh-
olds 0.2 and 0.8. Multiple testing for FMRP modules was corrected
at 5% FDR.
Extension of FMRP Modules
We aimed to find non-FMRP target genes with expression patterns
similar to FMRP modules. Using BrainSpan data and the WGCNA
R package ‘‘eigengene’’ function, we obtained a representative828 The American Journal of Human Genetics 93, 825–839, Novembbrain expression pattern, the ‘‘eigengene,’’ for each FMRP module.
We then calculated the correlation between each FMRP target and
the eigengene of its module. Subsequently, we obtained a set of
938 ‘‘module-1-like’’ genes as those non-FMRP target genes whose
expression pattern in BrainSpan was at least as correlated with the
FMRPmodule 1 eigengene as that of 50% of module 1 genes. Anal-
ogously, we obtained 339 module-2-like genes.
Functional annotations from MGI and HIS probabilities were
obtained for the module-like genes as above for the FMRP mod-
ules. Enrichments of module-like genes among genes disrupted
by de novo mutations in ASD were tested with the joint list of I-
exomes, SON-exomes, and T-BCAs. For an FMRP module, Fisher’s
test was used to test for a difference between the numbers of mod-
ule genes and module-like genes disrupted by de novo mutations
in ASD. Similarly, for rare deletion CNVs, the association between
the module-like gene sets and ASD was calculated with the Trend
test as for the FMRP modules.Results
FMRP Targets in ASD De Novo Single-Gene
Disruptions
A role for FMRP targets in ASD has recently been proposed
by Iossifov et al.11 on the basis of a significant enrichment
among genes disrupted by deleterious de novo point muta-
tions inASDprobands. To initially confirm, before refining,
the role played by FMRP targets in ASD, we first obtained
two lists of genes identified fromexome studies as disrupted
by particularly deleterious de novo mutations (nonsense,
frameshift, and splice-site variants) within ASD probands:
more specifically, the I-exomes from Iossifov et al.11 and
the SON-exomes from Sanders et al.,14 O’Roak et al.,12
and Neale et al.13 (see Material and Methods, Table S1).
We confirmed the enrichment of FMRP targets among
both I-exomes (4.5-fold, p¼ 6.073 107) and SON-exomes
(3.6-fold, p¼ 5.293 105). We additionally considered the
T-BCAs from Talkowski et al.26 (see Material and Methods,
Table S1) and again found an enrichment in FMRP targets
(4.4-fold, p ¼ 0.0003).
Because ASD is a neurodevelopmental disorder and
FMRP has been suggested to play a prominent role in the
brain,10 we also used logistic regression to test whether
FMRP targets are enriched among the ASD de novo sin-
gle-gene disruptions while accounting for relative brain
expression levels (see Material and Methods, Table S4).
Moreover, we simultaneously accounted for the CDS
length of genes, given that FMRP targets tend to be long
genes and such genes can be more often mutated by
chance. We indeed found that CDS length significantly
influenced the probability of a gene’s being disrupted by
de novo single-point mutations in ASD. By contrast, on
the basis of tissue expression from the GNF2 human atlas
(see Material and Methods), relative expression levels in
neither the fetal nor the adult brain were significantly
associated. After accounting for both CDS length and
relative gene expression levels in the adult brain, we
found that being targeted by FMRP significantly increased
the probability that a gene would occur in I-exomeser 7, 2013
(b ¼ 1.84, p ¼ 7.85 3 109), SON-exomes (b ¼ 1.80, p ¼
8.233 108), T-BCAs (b¼ 2.06, p¼ 2.583 106), and their
combination (b ¼ 1.62, p ¼ 9.61 3 1013) (Table S4). We
repeated the analysis by using fetal tissue expression with
very similar results: being targeted by FMRP significantly
increased the probability that a gene would occur in
I-exomes (b ¼ 1.81, p ¼ 4.97 3 109), SON-exomes (b ¼
1.66, p ¼ 6.31 3 107), T-BCAs (b ¼ 1.86, p ¼ 7.69 3
106), and their combination (b ¼ 1.53, p ¼ 1.79 3
1012) (Table S4). Thus, we broadened the enrichment of
FMRP targets in ASD de novo single-gene disruptions
and rejected the hypothesis that high relative brain expres-
sion or high CDS length explains the implication of FMRP
targets in ASD.
Four Modules of FMRP Targets
Given that many genes causally implicated in ASD are not
FMRP targets, we asked whether those FMRP targets that
might contribute to ASD are drawn generally from the
set of all FMRP targets or whether subsets of FMRP targets
with particular functions relevant to ASD etiology are pref-
erentially disrupted. Given the role of FMRP in neuronal
translational regulation, we examined whether the targets
of FMRP regulation might form distinct subgroups on the
basis of their differential regional and longitudinal expres-
sion within the human brain.
Clustering the 832 FMRP targets with available data
within a weighted gene coexpression network constructed
from highly detailed maps of gene expression in the brain
(BrainSpan;46 see Material and Methods) revealed four
robust gene modules with distinct spatiotemporal expres-
sion patterns and functional biases (Figure 1). In particular,
the two largest modules, module 1 (287 genes) andmodule
2 (230 genes), showed differential temporal expression:
whereas genes in module 1 tended to be specifically upre-
gulated during fetal development, genes in module 2
were generally upregulated in adolescence and adulthood.
The relatively small numbers of genes in modules 3 and 4
showed expression patterns with relatively more moderate
temporal variation than observed for module 1 or 2
(Figure 1A). Genes in module 3 (130 genes) were generally
more constantly expressed, whereas genes in module 4
(120 genes) tended to be upregulated during fetal develop-
ment but were still relatively more highly expressed during
other stages than genes in module 1.
To ascribe function to these modules’ genes, we consid-
ered GO Biological Process and Cellular Component anno-
tation terms,47 as well as the phenotypes that arise after the
disruption of the 1:1mouse ortholog of each of these genes
(provided by MGI;42 see Material and Methods). Conserva-
tively comparing modules to a background of all FMRP tar-
gets, we found that module 1 was significantly enriched
with genes annotated with terms relating to embryogen-
esis, transcriptional regulation, and chromatin organiza-
tion (Figure 1B and Table S5), whereas module 2 was
significantly enriched with genes annotated by terms
relating to synaptic function and seizures (Figure 1B andThe AmericanTables S6 and S7). No significant functional enrichments
were observed for the two smaller modules, modules 3
and 4. Given the opposing expression patterns and distinct
functional biases of modules 1 and 2, as well as the absence
of clear functional biases in modules 3 and 4, we took for-
ward only modules 1 and 2 for further analyses as exem-
plars of the diversity of FMRP targets. Nonetheless, we
considered and statistically accounted for the other mod-
ules throughout and return to considering them further
in the Discussion. Together, the genes in modules 1 and
2 account for 517/842 (61%) of all FMRP targets.
Given the differing functional biases of FMRP module 1
and 2 genes, we compared the brain specificity of the genes
within each of these modules by using data from the GNF2
gene expression atlas (Figure 1C). For both adult and fetal
tissues, we found that genes within module 2 were more
specific to the brain than those in module 1 (Mann-Whit-
ney U-test, adult p < 2.23 1016, fetal p ¼ 0.007) and that
bothmodules 1 and 2 had higher relative expression in the
brain than did the background of all genes (Mann-Whit-
ney U-test, for all comparisons p < 1 3 1014). These find-
ings are in good agreement with the functional biases and
together infer a more general neural developmental role
for module 1 genes and more specific synaptic roles for
module 2 genes.
To examine the likely deleteriousness of mutations in
module 1 and 2 genes, we first considered their probabili-
ties of being HIS. On the basis of predictions of haploinsuf-
ficiency by Huang et al.,43 we found significant enrich-
ments of predicted HIS genes in both module 1 (1.9-fold,
p ¼ 2.64 3 1015) and module 2 (1.3-fold, p ¼ 0.02;
Figure 1D). Moreover, module 1 had a significantly higher
proportion of predicted HIS genes than did module 2 (1.5-
fold, Fisher’s exact test, p ¼ 6 3 104). Confirming the
likely deleteriousness of mutations in these genes, we
found that genes frommodules 1 and 2 had a significantly
smaller proportion of common variation (MAF R 1%) in
the general population than did the background of all
genes (Mann-Whitney U-test, p ¼ 1.6 3 104 and p ¼
0.025, respectively; NHLBI Exome Variant Server data,
see Material and Methods and Table S8). Notably, genes
in module 1 had a significantly higher proportion of
ultra-rare variants than did those in module 2 (MAF <
0.02%; Mann-Whitney U-test, p ¼ 7.8 3 106), whereas
genes in module 2 had a significantly higher proportion
of rare-not-ultra-rare variants than did those in module 1
(0.02% % MAF < 1%; Mann-Whitney U-test, p ¼ 9.4 3
105). Our conclusions remained when we restricted our
analysis to variants more likely to damage protein function
(missense and splice-site mutations, change of stop co-
dons) (Figure 1E and Table S8). The observations that var-
iants in module 1 tended to be rarer than those in module
2 and that module 1 had a higher proportion of HIS genes
than did module 2 indicate that module 1 genes were sub-
ject to stronger negative selection than module 2 genes.
Taken together, our findings infer that mutations dis-
rupting the functioning of genes from both module 1Journal of Human Genetics 93, 825–839, November 7, 2013 829
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Figure 2. De Novo Single-Gene Disruptions in ASD Are Signifi-
cantly Enriched in FMRP Targets, Particularly in Module 1 Genes
Gene numbers are in parentheses. ns ¼ not significant at 5% FDR.
***p < 0.0001.and module 2 are likely to be phenotypically consequen-
tial but that mutations affecting module 1 genes are likely
to be more phenotypically consequential than those
affecting module 2 genes.ASD De Novo Single-Gene Disruptions Preferentially
Affect Genes in the Embryonically Upregulated FMRP
Module 1
Having characterized FMRPmodules 1 and 2, we wanted to
investigate to what extent they contribute to the enrich-
ment of FMRP targets among genes disrupted by delete-
rious de novo point mutations in ASD probands. On the
basis of the lists of variants from I-exomes, SON-exomes,
and T-BCAs as above (Table S1), we found that the enrich-
ment of FMRP targets was mainly due to highly significant
enrichments of module 1 genes (I-exomes: 5.3-fold, p ¼
9 3 104; SON-exomes: 5.6-fold, p ¼ 2 3 104; T-BCAs:
9.8-fold, p ¼ 5.2 3 105; Figure 2 and Table S9). By
contrast, FMRP module 2 was not significantly enriched
with I-exomes (2.12-fold, p ¼ 0.24) and had no overlap
with SON-exomes or T-BCAs. As for all FMRP targets, we
also used logistic regression to account for the CDS length
of genes (see Material and Methods). We found that mod-
ule 1 remained significantly associated with ASD de novo
gene disruptions in all three lists of I-exomes, SON-
exomes, and T-BCAs after CDS length had been accounted
for (Table S10).
For module 1, taken together with a high probability of
haploinsufficiency and the rarity of variation in the gen-
eral population as described above, the disruptions of
genes in this more embryonically expressed module of
FMRP targets provide strong evidence of these genes’ role
in ASD via highly penetrant, single-gene de novo muta-
tions.(D) Proportion of all FMRP target and module genes predicted to be
significant at *p < 0.05 or ***p < 0.0001.
(E) Differences in the proportion of nonsynonymous ultra-rare (MAF
variants between all FMRP targets and module genes. ns ¼ not signifi
most extreme point with a distance from the box% 1.5-fold the int
The AmericanCNV Pathway Analysis for Both Single- and Multiple-
Hit Etiologies
To examine the disruption of FMRP target genes by rare
deletion CNVs in ASD, we devised a test sensitive to the
number of FRMP targets disrupted within each individual.
In contrast to the de novo mutations considered above,
the vast majority of the CNVs considered here are in-
herited28,29,48 and thus by themselves are unlikely to
cause ASD. Nevertheless, such CNVs could contribute to
the ASD phenotype through environmental interactions
or, as reasoned in the Introduction, through the cumula-
tive effects of multiple genetic variants. Currently, gene-
set (‘‘pathway’’) analyses based on case-control CNV
data have predominantly employed one of two ap-
proaches. Each of these approaches considers genes that
are affected (‘‘hit’’) by CNVs by comparing either (1) the
number of pathway genes that are hit in cases against
the number of the same pathway genes hit in controls17
or (2) the proportion of cases with at least one hit in
the pathway to the equivalent proportion of controls
(‘‘Fisher’s test’’29).
The first approach does not take into account how
many individuals contribute the hit genes, whereas the
second method does not consider the number of genes
hit in the pathway. To account for both the number of in-
dividuals with a pathway hit by CNVs and the number of
times a pathway is hit within each individual, we devised
the Trend test, which is suitable for both single- and mul-
tiple-hit disease etiologies. In brief, we tested whether the
ratio of cases to controls with a number of pathway hits h
varies as the number of hits h increases (see Material and
Methods for further details). In a first step, we compared
the performance of this Trend test to the currently
applied Fisher’s test. Robustness and false-positive rates
for the Trend test and Fisher’s test were investigated
with extensive simulations for two data sets and five path-
ways of different sizes (see Appendix A). Although we
found that type-I-error rates for both tests tended to be
conservative, Fisher’s test was generally less sensitive
than the Trend test (Figure 3). Notably, at each signifi-
cance level, estimates of false-positive rates for both tests
decreased with pathway size and became less robust
(Figure 3).
Comparing the power of the Trend test to that of Fisher’s
test for a variety of scenarios, we found that even under a
single-hit disease model, the Trend test was more powerful
for the scenarios of interest (see Appendix A, Table S11).
Whereas the power of Fisher’s test did not change under
a multiple-hit model, the Trend test’s explicit modeling
of this phenomenon resulted in a further increase in
power.HIS are enriched among FMRP modules 1 and 2. Differences are
< 0.02%), rare (0.02%%MAF% 1%), and common (MAF > 1%)
cant. *p < 0.05, *p < 0.001, ***p < 0.0001. Error bars represent the
erquartile range.
Journal of Human Genetics 93, 825–839, November 7, 2013 831
=0.05=2×10-4
2×10-4
1×10-4
2.5×10-4
1.5×10-4
0.5×10-4
0 0
0.02
0.01
0.03
0.04
0.05
0.06
SP-rand, Fisher
NBS-rand, Fisher
SP-rand, Trend
NBS-rand, Trend
All
 FM
RP
FM
RP
 M
od
2
MG
I a
LTP
MG
I rL
TP
MG
I a
EP
Cs
MG
I a
SP
All
 FM
RP
FM
RP
 M
od
2
MG
I a
LTP
MG
I rL
TP
MG
I a
EP
Cs
MG
I a
SP
Target value
Figure 3. Trend and Fisher’s Test Comparison Using Empirical False-Positive Rates for Two Randomized Data Sets and Multiple
Pathway Sizes
Simulations were performed for randomized case-control data sets on the basis of SandersParents (SP-rand) andNBS (NBS-rand) data sets.
Random gene sets were matched to five pathways of different sizes: all FMRP targets (842 genes), FMRP module 2 (mod2) (239 genes),
MGI abnormal long-term potentiation (aLTP) (187 genes), MGI reduced long-term potentiation (rLTP) (122 genes), MGI abnormal excit-
atory postsynaptic currents (aEPCs) (104 genes), and MGI abnormal synaptic plasticity (aSP) (42 genes). Error bars represent the SE for
estimates from 100 random gene sets.Inherited Variation in ASD Is Associated with the
Postnatally Upregulated FMRP Module 2
Using our Trend test and considering rare deletion CNVs
and SNPs (Table S1), we asked whether FMRP targets and,
separately, the target genes in module 1 or 2 play a role
in inherited variation in ASD. In order to account for any
variation in mutational burden between cases and con-
trols, we deployed a method to calculate empirical p values
by comparing results obtained from randomized pathways
that we matched in both gene number and gene size
(Figure S2; see Material and Methods).
First, we compared the gene disruptions caused by
CNVs in 872 ASD probands to those disruptions in their
matched unaffected siblings from Sanders et al.28 (Table
1A). We found that the probands had significantly more
disruptions of all FMRP targets (Trend test p ¼ 0.0011;
empirical p ¼ 0.0016) and of module 2 genes in particular
(Trend test p ¼ 0.0012; empirical p ¼ 0.0017). We repli-
cated this in the expanded set of 1,124 probands
compared to their parents from Sanders et al.28 (FMRP tar-
gets: Trend test p ¼ 0.0039, empirical p ¼ 0.019; module
2: Trend test p ¼ 8 3 104, empirical p ¼ 0.0042; Table
1B). Finally, we replicated the result in an independent
data set of 561 ‘‘strict autism’’ probands and 1,146 unre-
lated unaffected controls from the AGP29 (FMRP targets:
Trend test p ¼ 2.8 3 105, empirical p ¼ 9 3 104; module
2: Trend test p ¼ 0.0014, empirical p ¼ 0.01; Table 1C).
These results affirm with replication that rare deletion
CNVs in ASD probands give rise to significantly more dis-
ruptions of FMRP targets, particularly genes in the postna-
tally upregulated module 2, than do rare deletion CNVs in832 The American Journal of Human Genetics 93, 825–839, Novembtheir parents, their unaffected siblings, and the general
control population.
We sought to formally test whether the risk of ASD for an
individual increases with the number of FMRP-target dis-
ruptions by rare deletion CNVs he or she possesses. Using
regression and calculating empirical p values, which
account for variation in mutational burden in cases (see
Material and Methods; Figure 4), we found that an
increased number of hits significantly increased the risk
of ASD for all FMRP targets in the Sanders et al. proband-
sibling cohort (empirical p ¼ 0.02), the Sanders et al.
proband-parent cohort (empirical p ¼ 0.0027), and
the AGP ‘‘strict ASD’’ proband-control cohort (empirical
p < 1 3 104). Similarly, we found that multiple disrup-
tions of FMRP module 2 genes significantly increased the
risk of ASD in the Sanders et al. proband-parent cohort
(empirical p ¼ 0.01); however, the clearly visible trend in
the Sanders et al. proband-sibling cohort was not signifi-
cant (Figure 4), and no multiple hits in module 2 were
observed in the AGP ‘‘strict ASD’’ proband-control cohort.
Notably, the Sanders et al. proband-parent cohort was
the largest of the three cohorts we examined, so a lack of
power in the two smaller cohorts could explain why sig-
nificance was not reached for them.
By definition, observations of rare deletion CNVs are
infrequent, and thus large data sets are needed for investi-
gating even those variants with large effects. Conse-
quently, we also wanted to consider the role of FMRP tar-
gets in ASD on the basis of the more common inherited
SNP variation. Although single SNPs are expected to have
very small effect sizes, for FMRPmodules 1 and 2, we coulder 7, 2013
Table 1. The Trend Test Shows that Disruptions of FMRP Targets andModule 2 Genes, Particularly by Rare Deletion CNVs, Are Significantly
Associated with ASD
Gene Set Trend Test p Value Cases with Hit Controls with Hit Empirical p Value
(A) ASD Matched Probands versus Siblings (Sanders)
Module 2a 0.0011 23 6 0.0016b
All FMRP targetsa 0.0012 54 29 0.0017b
Module 1 0.0066 23 8 0.0080b
(B) ASD Probands versus Parents (Sanders)
Module 2a 0.0008 26 21 0.0042b
All FMRP targetsa 0.0039 68 89 0.0193b
Module 1 0.0514 29 36 NA
(C) ASD Strict Cases versus Controls (AGP)
Module 2a 0.0014 8 2 0.0134b
All FMRP targetsa 2.76 3 105 20 9 0.0009b
Module 1 NA NA NA NA
A ‘‘hit’’ is defined as a rare deletion CNV overlapping a FMRP target or module gene such that at least one exon from every transcript is affected. Empirical p values
were obtained from 10,000 random gene sets matched for gene number and length (see Material and Methods). Gene sets with significant results in (A) were
validated in (B); likewise, results validated in (B) were tested for replication in (C). See Table S12 for modules 3 and 4. The following abbreviation is used: NA, not
applicable.
aThe empirical p value for a gene set is significant for (A)–(C) at 5% FDR (Benjamini-Hochberg).
bSignificant at 5% FDR (Benjamini-Hochberg).combine information across all autosomal SNPs located in
each module’s genes. Based on a GWAS data set on ASD-
affected families from AGRE (Table S1), SNP p values calcu-
lated with the transmission disequilibrium test were used
in a set-based association test in Plink.49 Accounting for
linkage disequilibrium of the SNPs at an r2 threshold of
0.5, we found that module 2 showed significant associa-
tion at 5% FDR (p ¼ 0.0062), whereas module 1 did not
(p¼ 0.28; Table S13).We retestedmodule 2 at r2 thresholds
of 0.2 and 0.8 and again found significant association (p ¼
0.0022 and p ¼ 0.0059, respectively).
We conclude that FMRP targets, and module 2 in partic-
ular, can be implicated in ASD via both rare deletion CNVs
and SNPs. Notably, we replicated the risk increase
conferred by multiple deletions of FMRP targets after
correction for mutational burden in cases, providing statis-
tically robust evidence of a multiple-hit disease etiology in
at least a subset of ASD cases and illustrating the Trend
test’s power to detect such etiologies.
FMRP Targets Are Associated with ASD More Than
Other Genes with Similar Brain Expression Patterns
Having differentially implicated FMRP modules 1 and 2 in
ASD, we investigated whether this association was either
generalizable to genes with expression patterns similar to
those of module 1 or 2 genes or else FMRP-target specific.
To this end, we compiled a list of 938 non-FMRP target
genes with expression patterns very similar to those of
module 1 genes (see Material and Methods); this list was
referred to as ‘‘module-1-like’’ genes. Analogously, 339
‘‘module-2-like’’ genes were also compiled. We found thatThe Americanmodule-1-like genes were not significantly enriched
among genes disrupted by deleterious de novo point muta-
tions in ASD probands (I-exomes, SON-exomes, and T-
BCAs joined: 1.38-fold, p ¼ 0.15). Comparing directly,
despite the much larger size of the module-1-like gene set
and a 1.54-fold higher total CDS length of module-1-like
genes, a deleterious de novo point mutation in an ASD pro-
band is 4.27-fold more likely to disrupt a module 1 gene
than a module-1-like gene (I-exomes, SON-exomes, and
T-BCAs joined: Fisher’s test p ¼ 7.33 3 105).
Unlike module 2 genes, module-2-like genes did not
show a significant association with ASD in any of the three
CNV data sets considered above in the Trend test (empir-
ical p > 0.05 for all three data sets).
These results show that the association between ASD
and both FMRP modules 1 and 2 does not apply to
non-FMRP target genes with highly similar expression
patterns in the human brain. We asked whether this
might be due to functional differences between the
FMRP modules and the module-like genes. Using func-
tional annotations obtained from MGI as above and
testing the overarching categories, we indeed found sig-
nificant differences (Figure 5): compared to the corre-
sponding module-like genes, both FMRP module 1 and
2 genes were significantly enriched in genes yielding a
nervous system phenotype when disrupted in mice (mod-
ule 1: 2.17-fold, Fishers’ p ¼ 2.35 3 104; module 2: 2.56-
fold, Fishers’ p ¼ 3.6 3 104). Moreover, looking at the
probability of haploinsufficiency, we found that both
FMRP module 1 and 2 genes were significantly more likely
to be HIS than the module-1-like or module-2-like genes,Journal of Human Genetics 93, 825–839, November 7, 2013 833
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An individual was defined to have h hits in a gene set if the individual’s rare deletion CNVs overlapped h genes in the gene set (see Ma-
terial and Methods). Using regression, we obtained the coefficient c for a linear increase in the proportion of cases among all individuals
with an increasing number of hits and the associated p value. We then obtained empirical p values by comparing the coefficient c to
corresponding coefficients calculated for 10,000 random gene sets (see Material and Methods). An asterisk indicates that a coefficient
is significant for the number of hits versus risk increase on the basis of linear regression at a threshold of 0.05.respectively (Figure 5; Wilcox p ¼ 2.52 3 106 and p ¼
2.98 3 103, respectively). Thus, FMRP target genes
from these two modules are both more sensitive to copy
loss and more likely to yield nervous system phenotypes
upon disruption than are non-FMRP target genes with
similar expression profiles.Discussion
In this work, we have dissected the role of FMRP target
genes in ASD by identifying distinct subpopulations of
FMRP targets and showing that these subpopulations are
differentially affected by different classes of genetic varia-
tion. Specifically, we showed that (1) FMRP targets can be
readily divided into subpopulations with distinct spatio-
temporal expression patterns and functional biases, that
(2) single-gene disruptions by de novo mutations in ASD
are highly enriched in an embryonically expressed sub-
group of FMRP targets, whereas (3) rare deletion CNVs
and, separately, SNPs in ASD are associated with a subgroup
of FMRP targets highly specific to the brain and upregu-
lated in adolescence and adulthood, and finally that (4)
FMRP targets within these two subgroups are more likely
to yield nervous system phenotypes upon copy loss than
are non-FMRP target genes with similar expression pat-
terns. Importantly, we developed a powerful CNV associa-
tion test that explicitly considers multiple-hit etiologies
and used it to demonstrate that the risk of ASD increases
with the number of disrupted FMRP target genes.
Our findings suggest that de novo mutations and in-
herited variation contribute to ASD through two different
genetic etiologies: (1) single highly penetrant de novo mu-
tations predominantly arising in genes encoding embry-
onic transcription factors and chromatin modifiers and
(2) multiple, often inherited, pathway disruptions particu-834 The American Journal of Human Genetics 93, 825–839, Novemblarly enriched in synaptic genes. Our findings are well sup-
ported by the direct functional assessment of FMRP targets
among disrupted genes in ASD (Tables S14–S16). Notably,
de novo CNVs that affect multiple genes might also
contribute to ASD via a multiple-hit mechanism resulting
from the cumulative effects of multiple simultaneously
copy-number-changed genes—for instance, region
16p11.2, with recurrent CNVs in autism,50 contains a total
of four FMRP targets (MAZ [MIM 600999], SEZ6L2, TAOK2
[MIM 613199], and ALDOA [MIM 103850], see Table S14).
Taken together, our findings provide a framework that is
based on the penetrance of a genetic variant and through
which previous ASD pathway analyses, which have sepa-
rately implicated synaptic genes17–20 and chromatin mod-
ifiers,12 can be unified. Etiologies that lie between these
two extremes could be found, and it will be of interest to
investigate to what extent less penetrant disruptions of
synaptic genes can modify phenotypes caused by highly
penetrant disruptions of embryonic transcription factors,
for example. The FMRP targets implicated here can be
used for prioritizing candidate genes for further study; in
particular, only 19 out of the 105 FMRP targets found dis-
rupted in ASD in this study are known ASD candidate
genes (Table S14). Crucially, we note that although an
enrichment of an FMRP target module among genes dis-
rupted in ASD probands supports a causal role in ASD for
biological processes represented by the module, it does
not imply that each and every disrupted module gene is
causal to the disorder. Moreover, there are types of genetic
variation that we have not examined. Among them are de
novomissensemutations within genes: these are alsomore
common in ASD probands than in their siblings11,14 but
less so than the highly deleterious de novo mutations
examined in this study, and the biological consequences
of missense mutations are less predictable. In addition,
although we have extensively analyzed rare deletioner 7, 2013
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(A) Module 1 and 2 genes were significantly more often annotated
to a nervous system phenotype than the corresponding module-
like genes (Fisher’s test), despite their similar expression patterns.
The only other significant difference is that module 2 genes
were less often annotated to an immune system phenotype from
MGI than module-2-like genes (0.4-fold, Fishers’ p ¼ 1.59 3
103).
(B) Different distributions in predicted HIS probabilities (Mann-
Whitney U-test). **p < 0.01, ***p < 103. Error bars represent
the most extreme point with a distance from the box % 1.5-fold
the interquartile range.CNVs, we initially did not consider rare duplication CNVs
because the two original studies by Sanders et al.28 and the
AGP29 found deletion CNVs to bemore likely to contribute
to ASD. In agreement with this, using the Trend test, we
found an association between FMRP targets and ASD via
rare duplication CNVs in the AGP cohort (empirical p ¼
0.018), but not in the two Sanders cohorts (empirical p >
0.05). Thus, the contribution of FMRP targets to ASD via
additional types of genetic variation remains unclear.
Initially, we subdivided FMRP targets into four modules,
but we observed distinct functional biases only for the two
largest modules (modules 1 and 2; Figure 1B), as compared
to the set of all FMRP targets, and thus we subsequently
characterized only these in detail. From the analysis of
gene disruptions in ASD, we found a significant enrich-
ment of module 3 genes among the two lists of genes dis-
rupted by damaging de novo mutations identified in
recent exome sequencing studies (I-exomes and SON-
exomes; Table S9). However, using a correction for gene
length, we found that module 3 was significantly associ-
ated with ASD via de novo damagingmutations in all three
lists of I-exomes, SON-exomes, and T-BCAs (Table S10). ByThe Americancontrast, applying the Trend test to rare deletion CNVs in
ASD, we found that module 4 was significantly associated
with ASD in only two of the three data sets we considered
(Table S12). There was no other evidence of an association
between ASD and module 3 or 4 (Tables S9, S12, and S13).
The proportion of predicted HIS genes and the single-
nucleotide variation in the general population for modules
3 and 4 imply that the deleteriousness of mutations in
module 3 and 4 genes lies between that of modules 1 and
2 (Figures S1 and S3) and that there is a significant differ-
ence in haploinsufficiency probabilities between modules
2 and 3, but no significant difference between modules 1
and 3. Because module 3 genes are typically expressed
throughout development, in agreement with the high
probabilities of haploinsufficiency, theymight play biolog-
ical roles indispensable for embryonic stages onward, thus
conforming closely to the two distinct genetic etiologies
suggested above. Unfortunately, because of the relative
small number of module 3 genes and the resulting lack of
power, we could not determine this via functional enrich-
ment analyses. As regulation by FMRP targeting is further
elucidated, the functional interpretation of these smaller
clusters of coexpressed genes might become clearer.51,52
The coexpression patterns of the 105 FMRP targets affected
by the de novo single-gene mutations and rare deletion
CNVs considered in this study confirm this modular
pattern in that the genes from modules 3 and 4 link the
more distinct clusters of disrupted genes from module 1
and, separately,module 2 (Figure S4; Appendix A). Notably,
we found that non-FMRP target genes with brain expres-
sion patterns highly similar to those of FMRP module 1
and 2 genes did not show a strong association with ASD.
Our systemic insight into the role of particular subpopu-
lations of FMRP targets in ASD is suggestive of etiological
progression. It is plausible that a number of the earlier ex-
pressedmodule 1 FMRP targets are involved in establishing
or maintaining the same neurological processes that the
later expressed synaptically focusedmodule 2 FMRP targets
participate in. Unfortunately, the data are currently too
sparse to establish whether module 2 gene expression is
under the control of earlier expressed FMRP target genes.
Nonetheless, the participation in shared processes would
also explain how the disruption of different genes gives
rise to a common phenotype. This participation would
also suggest that the same process can be disrupted at
different time points and have important therapeutic con-
sequences for ASD: ASD-associated module 2 genes, often
expressed at the synapse in adolescence and adulthood,
might be far more therapeutically attractive targets for
modulating this process than module 1 genes, often tran-
scriptional regulators that are upregulated embryonically.
Indeed, it has been shown recently that some symptoms
in a mouse model of ASD can be rescued at a juvenile
stage.53 The evidence that we found for a multiple-hit eti-
ology in ASD is consistent with two different mechanisms
of disease onset: (1) in an additive model, each disruption
of relevant biological processes leads to an increase in ASDJournal of Human Genetics 93, 825–839, November 7, 2013 835
traits until ASD is diagnosed; and (2) in a threshold model,
ASD emerges as soon as the mutational load affecting rele-
vant biological processes exceeds a critical threshold.
Further support for an additive model stems from the
observation that unaffected parents in families with multi-
ple affected children score higher on the broader autism
phenotype assessment than do parents in families with
only one affected child.54,55
The Trend test, which we developed to investigate multi-
ple-hit contributions to ASD, is applicable to any complex
genetic condition. From the results of our simulations, we
provide the statistically founded recommendation to only
consider gene sets with at least 100 genes for the initial
stage of a CNV pathway analysis (Figure 3). For gene sets
with a significant result in the initial stage, it is then
possible to test smaller subsets in a second step. The Trend
test will be particularly useful for highly polygenic disor-
ders for which approaches that consider single genetic
loci in isolation cannot readily uncover all causal variants
(classically known as the ‘‘missing heritability’’56). More-
over, the Trend test can readily combine information
from multiple types of genetic variants (structural or
nucleotide variation), increasing its potential use with
the advent of next-generation sequencing techniques.Appendix A
Temporal Specificity of FMRP Targets
When investigating temporal specificity of FMRP target
modules, we noticed that all FMRP targets had generally
lower median RPKM measure C for the ‘‘child’’ stage. This
was also the case for all genes contained in the BrainSpan
data set and was potentially an experimental artifact.
Consequently, we chose to increase C by a constant factor
F(C) for each gene when looking at temporal specificity
only and calculated it as follows.
For each gene g, let M(g,s) be the median expression in
stage s. For each stage s, let
SðsÞ ¼ mediangenes gðMðg; sÞÞ: ThenFðCÞ ¼ Sðearly fetalÞ þ Sðlate fetalÞ þ SðinfantÞ þ SðadolescentÞ þ SðadultÞ
53 SðchildÞ :For all FRP targets, we calculated F(C) ¼ 1.9773 (which is
close to 1.9032, obtained when all genes in BrainSpan
were used).
Trend and Fisher’s Tests for CNVs
The details for the Trend test are as follows. Define U and A
as the numbers of unaffected and affected individuals,
respectively, in the data set: N ¼ A þ U. Let m be
themaximumnumber of hits for a pathway in any individ-836 The American Journal of Human Genetics 93, 825–839, Novembual, let U(h) and A(h) be the number of unaffected and
affected individuals, respectively, with exactly h hits
in the pathway: h ¼ 0, 1, ..., m. Also, let
m0 ¼minðhj:AðhÞ < 5 and UðhÞ < 5Þ. We defined adjusted
numbers U0(h) ¼ U(h) and A0(h) ¼ A(h) for h ¼ 0, 1, ..., m0
 1 and U 0 ðm0 Þ ¼Pmh¼m0UðhÞ, A0 ðm0 Þ ¼Pmh¼m0AðhÞ. The
Trend test statistic is
T ¼
Xm0
h¼0
ﬃﬃﬃ
h
p 
A
0 ðhÞU  U 0 ðhÞA2;
for which
varðTÞ ¼ A3U
N
 Xm0
h¼0
hH
0 ðhÞN H 0 ðhÞ

Xm0 1
h¼0
Xm0
k¼hþ1
2
ﬃﬃﬃﬃﬃ
hk
p
H
0 ðhÞH 0 ðkÞ
!
;
where H0(h) ¼ A0(h) þ U0(h) for h ¼ 0, 1, ..., m0. According
to the results of Cochran and Armitage,
T=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
varðTÞp  Nð0; 1Þ, i.e., T= ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃvarðTÞp , follows a standard
normal distribution.
Comparison of Trend Test to Fisher’s Test
To compare robustness and false-positive rates for the
Trend test and Fisher’s test, we carried out simulations by
creating randomized sets based on two different data
sets: rare deletion CNVs in the parents of children with
autism from Sanders et al.28 (SandersParents) and deletion
CNVs in the NBS data set. To investigate the effect of vary-
ing gene numbers within pathways, we chose five example
pathways representing a wide range of gene counts
(Figure 3) and matched 100 random gene sets by gene
number and gene length to each example pathway. The
simulations consisted of 10,000 random splits of individ-
uals from either the SandersParents or NBS data sets into
cases and controls and were followed by the calculation
of Trend and Fisher’s test statistics for the random gene
sets; we then estimated the false-positive rates of the Trend
and Fisher’s tests for the corresponding pathway size at sig-
nificance levels 0.05 and 2 3 104.To compare the power of the Fisher’s and Trend tests, we
obtained association p values from both tests for a variety
of scenarios: a data set (1) of either 800 cases and 800 con-
trols or 600 cases and 600 controls; (2) with between 10
and 10% of controls possessing one hit; and (3) with a ratio
of cases to controls with one hit equal to r in (1.5, 2, 2.5, 3,
3.5, 4). To avoid further assumptions about the increase in
risk conferred by multiple hits, initially no individual was
assumed to have more than one hit.er 7, 2013
SNP Pathway Analysis
Following the additional quality-control steps of Wang
et al.,32 we removed all monozygotic twins and sample du-
plicates (as detailed in the download information) and
excluded individuals with a call rate< 0.95.We usedmulti-
dimensional scaling in Plink49 (v.1.07) to identify individ-
uals of European descent and matched the parameters of
Wang et al.32 as closely as possible. We manually looked
through 11 pairs of genotype duplicates and trisomy 21
cases from the paper by Wang et al.32 and excluded one
case still found in the data set. Finally, we excluded SNPs
with a MAF < 0.05 and Hardy-Weinberg equilibrium p <
0.001.
BrainSpan Gene Correlation Network
The BrainSpan gene expression data as described in the
Material and Methods were used for building a gene cor-
relation network. Genes with less than one RPKM in
more than 95% of the samples were excluded. For all
samples, we calculated Pearson’s correlation coefficient
for all gene pairs. A network was built with genes as no-
des and edges between two genes weighted with their
correlation coefficient r. Considering only edges with
weight r R 0.5 gave 14,886 unique genes with at least
one edge.
We calculated the number of links between the FMRP
targets disrupted in ASD probands by de novo single-
gene mutations and rare deletion CNVs (Table S14). We
then obtained an empirical one-sided p value by
comparing random gene sets as follows.
Of the FMRP targets disrupted in ASD probands by de
novo single-gene mutations (in the lists of I-exomes,
SON-exomes, and T-BCAs; see Material and Methodsand
Results), 34 genes were in the correlation network; of the
FMRP targets disrupted by rare deletion CNVs, but not by
de novo single-gene mutations, 69 were in the correlation
network. In each of 10,000 simulations performed, we
1. chose 34 out of the 141 genes from I-exomes, SON-
exomes, and T-BCAs (these were in the correlation
network)
2. chose 69 out of 1,246 genes disrupted in ASD pro-
bands by rare deletion CNVs in the data sets from
AGP (strict ASD) and Sanders (see Material and
Methods) (these were in the correlation network,
but not in the 141 genes from I-exomes, SON-
exomes, or T-BCAs)
3. calculated the number of links between all 34þ 69¼
103 genes chosen in steps 1 and 2.
We found that there weremore links between the disrup-
ted FMRP targets than between any of the random gene
sets (giving an empirical p value of 104; Figure S5). To
confirm robustness of our results, we repeated the experi-
ment with more stringent correlation thresholds for links
in the network. For correlation thresholds 0.6, 0.7, 0.8,
and 0.9, there were significantly more links between theThe Americandisrupted FMRP targets than between random gene sets
(empirical p values of 104, 2.9 3 103, 0.042, and 0.027,
respectively; Figure S5).Supplemental Data
Supplemental Data include 5 figures and 16 tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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